Naveen Pemmaraju: Important paper on AML and Hyperleukocytosis
Naveen Pemmaraju shared a post about a paper titled “Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis” published in JCO Oncology Practice.
Authors: Fadi G. Haddad, Koji Sasaki, Jayastu Senapati, Lianchun Xiao, Grace Park, Tareq Abuasab, Sangeetha Venugopal, Daniel Rivera, Alexandre Bazinet, Rodrick Babakhanlou, Kunhwa Kim, Faustine Ong, Sai Desikan, Naveen Pemmaraju, Sanam Loghavi, Gautam Borthakur, Courtney DiNardo, Hussein A. Abbas, Nicholas J. Short, Naval Daver, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian and Tapan Kadia.
“Important new paper just out in JCO Oncology Practice led by Dr. Fadi Haddad and Tapan Kadia. .
Outcomes of Patients with Newly Diagnosed AML and Hyperleukocytosis.”
Source: Naveen Pemmaraju/X
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network.
He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023